eli lilly gip glp-1 Retatrutide is a next-generation “triple agonist” weight loss drug currently in development by Eli Lilly | My Reta News

Retatrutide, the triple receptor (GLP-1, GIP, glucagon) most potent weight loss drug yet seen (w/ 28% body weight reduction), pushes the limits, introduces some risks, by @PostRowland gift link https://t.co/v9XrXc7vBJ

22.46

★★★★☆4.8 (126)

New clinical trial data from Eli Lilly shows its GLP-1 daily weight loss pill can reduce body weight by up to 11% over time. ABC News medical correspondent Dr. Darien Sutton joins

29.24

★★★★★4.9 (98)

GLP-1 Competitive Environment

22.24

★★★★★5.0 (157)

We're taking a closer look at Foundayo™ (orforglipron), the upcoming oral GLP-1/GIP receptor agonist from Eli Lilly. Unlike traditional treatments that require injections, this daily pill offers incredible flexibility. Take it anytime,

25.44

★★★★★4.7 (84)

GLP4 coming out Eli Lilly will release animal study data for at QUINTUPLE AGONIST at #ADA2026 For reference: Semaglutide= GLP1 Tirzepatide = GLP1/GIP Retatrutide = GLP1/GIP/Glucagon New Mol = GLP1/GIP/Glucagon/Amylin/Calcitonin Early rat

21.12

★★★★★4.9 (203)

Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound?

25.71

★★★★★5.0 (176)

Lilly's KwikPen Delivers Month of Zepbound GLP-1 in One Device

27.38

★★★★★4.8 (132)